Table 2.
Macroscopic and microscopic features
| Variable | No. (%) |
|---|---|
| Macroscopic features | |
| TNM stage | |
| IB | 1 (3.8) |
| IIB | 3 (11.5) |
| IIIA | 2 (7.7) |
| IIIB | 2 (7.7) |
| IV | 18 (69.2) |
| Locationa | |
| Left lower lobe | 3 (11.5) |
| Left upper lobe | 6 (23.1) |
| Right lower lobe | 4 (15.4) |
| Right upper lobe | 12 (46.2) |
| Central | 8 (30.8) |
| Peripheral | 18 (69.2) |
| Microscopic features | |
| Subgroupb | |
| Pleomorphic carcinoma | 9 (47.4) |
| Spindle cell carcinoma | 7 (36.8) |
| Giant cell carcinoma | 2 (10.5) |
| Carcinosarcoma | 0 |
| Pulmonary blastoma | 0 |
| Undetermined | 1 (5.3) |
| EGFR mutationc | |
| Positive | 2 (18.2) |
| Negative | 9 (81.8) |
| PD-L1 expressiond | |
| High expression (TPS ≥ 50%) | 8 (61.5) |
| Low expression (1 ≤ TPS < 50%) | 4 (30.8) |
| Negative (TPS < 1%) | 1 (7.7) |
TNM, tumor, node, metastasis; EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand 1; TPS, tumor proportion score.
a
The dominant lobe could not be determined in one patient because the primary lesion was seen as consolidation in both upper lobes.
b
Pathologic review and subgroup classification were conducted in 19 patients.
c
EGFR mutation test was performed in 11 patients.
d
PD-L1 test was performed in 13 patients.